{"entity": "journal", "iuid": "793b97387a3e4bd897c46fe1fbbd2354", "timestamp": "2026-11-07T11:13:58.308Z", "links": {"self": {"href": "https://publications.scilifelab.se/journal/Neuro%20Endocrinol.%20Lett..json"}, "display": {"href": "https://publications.scilifelab.se/journal/Neuro%20Endocrinol.%20Lett."}}, "title": "Neuro Endocrinol. Lett.", "issn": "2354-4716", "issn-l": "0172-780X", "publications_count": 4, "publications": [{"entity": "publication", "iuid": "1f4e4d96c44643488989943e6820d31a", "links": {"self": {"href": "https://publications.scilifelab.se/publication/1f4e4d96c44643488989943e6820d31a.json"}, "display": {"href": "https://publications.scilifelab.se/publication/1f4e4d96c44643488989943e6820d31a"}}, "title": "Antibody reactivity in cerebrospinal fluid and serum against the insulin-insulin-like growth factor 2 (INS-IGF2) protein is associated with psychotic symptomatology in patients with schizophrenia or related psychosis.", "authors": [{"family": "Melkersson", "given": "Kristina", "initials": "K"}], "type": "journal article", "published": "2025-04-28", "journal": {"title": "Neuro Endocrinol. Lett.", "issn": "2354-4716", "volume": "46", "issue": "1", "pages": "1-14", "issn-l": "0172-780X"}, "abstract": "Evidence has accumulated that an autoimmune-mediated process may underlie development of schizophrenia, and in two recent studies, we found increased antibody reactivity against the insulin receptor-A (INSR-A) and insulin-like growth factor 1 receptor (IGF1R) and their ligands (insulin and insulin-like growth factor 1) in cerebrospinal fluid (CSF) and/ or serum from patients with schizophrenia or related psychosis. The aim of this study was to analyze antibody reactivity in schizophrenia against the insulin-insulin-like growth factor 2 (INS-IGF2) protein, which hypothetically also may be a ligand to INSR-A and IGF1R and involved in the pathogenesis of schizophrenia.\n\nPatients with schizophrenia or related psychosis and controls were analyzed regarding antibody reactivity against INS-IGF2 in CSF (n = 12/ n = 11) and serum (n = 17/ n = 11), using bead-based antigen arrays of one protein fragment and 24 peptides of this protein. Additionally, the patients were assessed for clinical symptoms with the Positive and Negative Syndrome Scale (PANSS) for schizophrenia.\n\nSignificantly higher antibody reactivity against the peptides 11 and 12 was found in patients in partial than full symptom remission. Patients' antibody reactivity against the peptides 5, 11 and 12 correlated positively to their PANSS scores of positive symptoms. Furthermore, significantly higher antibody reactivity against the peptides 2, 3, 10 and 22 was found in patients with, than without, heredity for diabetes mellitus type 1 or 2.\n\nThe findings in this study pointed that the INS-IGF2 protein may be present in the CNS and involved in the autoimmune-mediated process underlying the development of schizophrenia.", "doi": null, "pmid": "40319454", "labels": {"Autoimmunity and Serology Profiling": "Service"}, "xrefs": [{"db": "pii", "key": "46012502"}], "notes": [], "created": "2025-09-10T08:13:51.362Z", "modified": "2026-10-22T06:43:24.030Z"}, {"entity": "publication", "iuid": "b6d27f8c7d2c449ca75863e2f4bec72f", "links": {"self": {"href": "https://publications.scilifelab.se/publication/b6d27f8c7d2c449ca75863e2f4bec72f.json"}, "display": {"href": "https://publications.scilifelab.se/publication/b6d27f8c7d2c449ca75863e2f4bec72f"}}, "title": "Increased antibody reactivity against insulin receptor-A and insulin like growth factor 1 receptor and their ligands in cerebrospinal fluid and serum of patients with schizophrenia or related psychosis.", "authors": [{"family": "Melkersson", "given": "Kristina", "initials": "K"}, {"family": "Bensing", "given": "Sophie", "initials": "S", "orcid": "0000-0002-9193-2860", "researcher": {"href": "https://publications.scilifelab.se/researcher/acae2ad8ca844588b2b850c863034b7b.json"}}], "type": "journal article", "published": "2021-09-10", "journal": {"title": "Neuro Endocrinol. Lett.", "issn": "2354-4716", "issn-l": "0172-780X", "volume": "42", "issue": "5", "pages": "339-358"}, "abstract": "Evidence has accumulated that an autoimmune-mediated process in the central nervous system may underlie the development of schizophrenia. Various antibodies have also previously been detected in serum of patients with schizophrenia. Therefore, the aim of this study was to analyze antibody reactivity against proteins, selected based on potential schizophrenia disease relevance, in both cerebrospinal fluid and serum of patients with schizophrenia.\r\n\r\nCerebrospinal fluid and serum from 17 patients with schizophrenia or related psychosis and 12 controls were analyzed regarding antibody reactivity, using bead-based antigen arrays of protein fragments or peptides of 21 selected proteins. Additionally, the patients were accessed for clinical symptoms with the Positive and Negative Syndrome Scale (PANSS) for schizophrenia.\r\n\r\nIncreased antibody reactivity was found in patients compared to controls against the insulin receptor (INSR), PAGE2B;2;5 and heat shock proteins (HSPs) in both cerebrospinal fluid and serum, and against the insulin like growth factor 1 receptor (IGF1R), insulin (INS), insulin like growth factor 1 (IGF1), cadherin 5 (CDH5), nerve growth factor (NGF) and vascular endothelial growth factor A (VEGFA) in serum alone. Moreover, patients' antibody reactivity in serum against PAGE2B;2;5, IGF1R or NGF correlated positively to their PANSS scores.\r\n\r\nTaken together, these results point to that an autoimmune-mediated process underlies the development of a core group of schizophrenia cases and that the INSR and IGF1R, their ligands (INS and IGF1) and related inter- and intracellular proteins (CDH5, PAGE2B;2;5, HSPs, NGF and VEGFA) may constitute antigen targets.", "doi": null, "pmid": "34506098", "labels": {"Autoimmunity and Serology Profiling": "Service"}, "xrefs": [{"db": "pii", "key": "NEL420521A09"}], "notes": [], "created": "2021-12-01T08:57:34.170Z", "modified": "2025-11-17T10:02:08.406Z"}, {"entity": "publication", "iuid": "bd6cc0589fdb4e1d93caa541c88748eb", "links": {"self": {"href": "https://publications.scilifelab.se/publication/bd6cc0589fdb4e1d93caa541c88748eb.json"}, "display": {"href": "https://publications.scilifelab.se/publication/bd6cc0589fdb4e1d93caa541c88748eb"}}, "title": "Evidence for a negative association between schizophrenia and a polymorphism in the insulin receptor substrate-3 (IRS-3) gene.", "authors": [{"family": "Melkersson", "given": "Kristina", "initials": "K"}, {"family": "Persson", "given": "Bengt", "initials": "B"}], "type": "journal article", "published": "2012-05-29", "journal": {"volume": "33", "issn": "0172-780X", "issue": "3", "pages": "321-330", "title": "Neuro Endocrinol. Lett.", "issn-l": null}, "abstract": "Since there are clear indications that schizophrenia is a systemic disorder, we sought for a common molecular basis for schizophrenia abnormalities in brain and body. Our hypothesis was that an impaired insulin and insulin-like growth factor signalling in cells might underlie changes in both brain and body in schizophrenia. In this regard, the insulin receptor substrates 1-4, linking both the insulin and insulin-like growth factor-1 receptors with intracellular pathways, might be of interest to study genetically. In the present study, we chose to study the insulin receptor substrate-3 (IRS-3) gene as a candidate gene in schizophrenia.\r\n\r\nThe IRS-3 gene of 93 patients with the diagnosis of schizophrenia according to DSM-IV criteria and 57 healthy control subjects was screened for DNA sequence variations, followed by case-control analyses of total 10 detected polymorphisms.\r\n\r\nThe A/G genotype of the single nucleotide polymorphism (SNP) rs117078492 in the IRS-3 gene occurred in 5.3% of the control subjects compared with in 0% of the patients (p=0.05). Similarly, the haplotypes 5 and 3X, constructed from polymorphisms in the IRS-3 gene and including the A allele of this A/G SNP, occurred only in the control subjects and not in the patients (5.3% vs 0%, p=0.05).\r\n\r\nOur findings suggest that individuals carrying the A allele of this A/G SNP in the IRS-3 gene as well as the estimated haplotypes 5 or 3X including this A allele, have a protection against schizophrenia development.", "doi": "10.1016/S0924-9338(13)77131-1", "pmid": "22635093", "labels": {"National Genomics Infrastructure": null, "NGI Uppsala (Uppsala Genome Center)": null}, "xrefs": [{"db": "pii", "key": "NEL330312A01"}], "notes": [], "created": "2017-05-04T14:57:39.236Z", "modified": "2020-01-21T13:56:10.388Z"}, {"entity": "publication", "iuid": "1f50059e02074a5e873a48572d7e242e", "links": {"self": {"href": "https://publications.scilifelab.se/publication/1f50059e02074a5e873a48572d7e242e.json"}, "display": {"href": "https://publications.scilifelab.se/publication/1f50059e02074a5e873a48572d7e242e"}}, "title": "Association between body mass index and insulin receptor substrate-4 (IRS-4) gene polymorphisms in patients with schizophrenia.", "authors": [{"family": "Melkersson", "given": "Kristina", "initials": "K"}, {"family": "Persson", "given": "Bengt", "initials": "B"}], "type": "journal article", "published": "2011-12-15", "journal": {"volume": "32", "issn": "0172-780X", "issue": "5", "pages": "634-640", "title": "Neuro Endocrinol. Lett.", "issn-l": null}, "abstract": "The insulin receptor substrate-4 (IRS-4) protein is highly expressed in the hypothalamus that plays a main role in the regulation of body weight. Therefore, as overweight and obesity are more frequent in patients with schizophrenia compared to the general population, this study was undertaken to investigate potential associations between body mass index (BMI) or height and polymorphisms in the IRS-4 gene in schizophrenia patients and healthy controls.\n\nThe IRS-4 gene of 93 patients and 59 controls was screened for DNA sequence variations, and then 10 detected single nucleotide polymorphisms (SNPs) were investigated in relation to BMI and height of patients and controls.\n\nMean BMI was higher in patients than in controls, whereas there was no difference regarding height. Significant associations were found between patients' BMI and genotypes of six SNPs (rs1801164, rs80131334, rs41307415, rs73253702, rs1801162, rs2073114) or a haplotype including these six SNPs. In contrast, no associations were found between BMI or height of controls, or height of patients, and the genotypes or haplotypes.\n\nThis study clearly demonstrates associations between BMI and IRS-4 variants in schizophrenia patients, but not in healthy controls, pointing to a possible involvement of IRS-4 in the control of body weight in schizophrenia.", "doi": null, "pmid": "22167131", "labels": {"National Genomics Infrastructure": null, "NGI Uppsala (Uppsala Genome Center)": null}, "xrefs": [{"db": "pii", "key": "NEL320511A07"}], "notes": [], "created": "2017-05-04T14:57:22.545Z", "modified": "2021-07-05T12:39:53.472Z"}], "created": "2017-05-09T09:12:33.533Z", "modified": "2020-11-27T13:14:10.001Z"}